Consistent with our results, GSKJ-4 treatment did decrease the expression of JMJD3 in fibroblast-like synoviocytes (Jia et al., 2018), breast cancer stem cells (Yan et al., 2017) and renal interstitial fibroblasts in vitro (Yu et al., 2021). The gene discussed is KDM6B; the disease is breast cancer.